Aktis Oncology (NASDAQ:AKTS) Now Covered by Bank of America

Bank of America started coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a research note released on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $34.00 price target on the technology company’s stock.

Other analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Leerink Partners started coverage on Aktis Oncology in a research note on Tuesday. They set an “outperform” rating and a $31.00 price objective on the stock. Finally, TD Cowen initiated coverage on Aktis Oncology in a research note on Tuesday. They issued a “buy” rating for the company. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $31.67.

Aktis Oncology Stock Down 4.9%

Aktis Oncology stock opened at $20.90 on Tuesday. Aktis Oncology has a 52-week low of $18.52 and a 52-week high of $29.16.

Insider Activity at Aktis Oncology

In other news, major shareholder Vida Ventures Ii, Llc acquired 835,000 shares of Aktis Oncology stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average cost of $18.00 per share, with a total value of $15,030,000.00. Following the transaction, the insider directly owned 5,671,825 shares of the company’s stock, valued at $102,092,850. This trade represents a 17.26% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Ecor1 Capital, Llc acquired 2,222,222 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $39,999,996.00. Following the purchase, the director owned 4,348,658 shares of the company’s stock, valued at $78,275,844. The trade was a 104.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 6,117,776 shares of company stock worth $110,119,968 in the last three months.

Aktis Oncology News Summary

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: Several major firms initiated coverage with bullish ratings and high price targets — Bank of America (Buy, $34 PT), Leerink Partners (Outperform, $31 PT), and JPMorgan (Overweight, $30 PT) — implying 43–63% upside vs. the current price, giving institutional validation to AKTS’s strategy and growth potential.
• Positive Sentiment: TD Cowen started coverage with a Buy, highlighting Aktis’s differentiated miniprotein radiopharma platform and projecting multi‑billion dollar sales potential; this initiation is also covered in TipRanks commentary. AKTS initiated with bullish view at TD Cowen — The Fly TipRanks coverage
• Positive Sentiment: Leerink and JPMorgan notes are summarized in market wire coverage, reinforcing the consensus bullish view from new analysts. Leerink/JPMorgan coverage — Benzinga
• Neutral Sentiment: Short-interest reports for early February show “0 shares” and NaN changes — likely data errors or reporting anomalies; current filings do not provide reliable evidence of elevated short pressure or a squeeze scenario.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.